It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
IL-33, which is a crucial modulator of adaptive immune responses far beyond type 2 response, can enhance the function of several T cell subsets and maintain the immune homeostasis. However, the contribution of IL-33 to double negative T (DNT) cell remains unappreciated. Here, we demonstrated that the IL-33 receptor ST2 was expressed on DNT cells, and that IL-33 stimulation increased DNT cells proliferation and survival in vivo and in vitro. Transcriptome sequencing analysis also demonstrated that IL-33 enhanced the biological function of DNT cells, especially effects on proliferation and survival. IL-33 promoted DNT cells survival by regulating Bcl-2, Bcl-xl and Survivin expression. IL-33-TRAF4/6-NF-κB axis activation promoted the transmission of essential division and survival signals in DNT cells. However, IL-33 failed to enhance the expression of immunoregulatory molecules in DNT cells. DNT cells therapy combined with IL-33 inhibited T cells survival and further ameliorated ConA-induced liver injury, which mainly depended on the proliferative effect of IL-33 on DNT cells in vivo. Finally, we stimulated human DNT cells with IL-33, and similar results were observed. In conclusion, we revealed a cell intrinsic role of IL-33 in the regulation of DNT cells, thereby identifying a previously unappreciated pathway supporting the expansion of DNT cells in the immune environment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Beijing Friendship Hospital, Capital Medical University, Department of International Medical Center, Beijing, China (GRID:grid.411610.3) (ISNI:0000 0004 1764 2878)
2 Beijing Friendship Hospital, Capital Medical University, Department of Infectious Diseases, Beijing, China (GRID:grid.411610.3) (ISNI:0000 0004 1764 2878)
3 Capital Medical University Forth Clinical School, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
4 Capital Medical University, Liver Research Center, Beijing Friendship Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X); Beijing Key Laboratory of Translational Medical On Liver Cirrhosis, Beijing, China (GRID:grid.24696.3f); National Clinical Research Center for Digestive Diseases, Beijing, China (GRID:grid.512752.6)